Regulatory approval

Published by the Health Service Executive. Approved

Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer

This is written in the approval document.

Reimbursement

CDS

Citation

Exemestane Monotherapy, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6568/376_Exemestane_therapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) ER positive, PR positive Invasive Breast Carcinoma Exemestane
HSE (1) ER positive Invasive Breast Carcinoma Exemestane
HSE (1) PR positive Invasive Breast Carcinoma Exemestane